Toleranzia Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • TOL

Stock Symbol

  • Share Price
  • $0.05
  • (As of Friday Closing)

Toleranzia General Information

Description

Toleranzia AB is a pharmaceutical company based in Sweden. The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.

Contact Information

Website
www.toleranzia.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Erik Dahlbergsgatan 11A
  • 411 26 Gothenburg
  • Sweden
+46 076-319 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Toleranzia Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.05 $0.05 $0.04 - $0.13 $5.35M 110M 127K

Toleranzia Financials Summary

In Thousands,
USD 		TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 6,523 7,536 458 4,827
Revenue 0 0 0 0
EBITDA (829) (850) (730) (531)
Net Income (814) (834) (728) (531)
Total Assets 11,221 12,043 14,611 8,847
Total Debt 0 81 94 104
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Toleranzia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Toleranzia‘s full profile, request access.

Request a free trial

Toleranzia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Toleranzia AB is a pharmaceutical company based in Sweden. The company's drug candidate, TOL2, is being developed for th
Drug Discovery
Gothenburg, Sweden
4 As of 2022
00.000
0.000 0000-00-00
00000000 00.000

000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
000000000000000
Silver Spring, MD
000 As of 0000
00000
0000 00000

000000

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Toleranzia Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
United Therapeutics Formerly VC-backed Silver Spring, MD 000 00000 0000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 00 00000 0000000000.
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
000000 00000000 Formerly VC-backed Foster City, CA 00000 000.00 000000000 000.00
000 00000 Corporation Indianapolis, IN 00000 000.00 000000000 000.00
You’re viewing 5 of 18 competitors. Get the full list »

Toleranzia Patents

  • 15

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Toleranzia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2011321051-B2 New compositions and methods for treatment of autoimmune and allergic diseases Inactive 28-Oct-2010 00000000000
AU-2011321051-A1 New compositions and methods for treatment of autoimmune and allergic diseases Active 28-Oct-2010 00000000000
CA-2795577-A1 New compositions and methods for treatment of autoimmune and allergic diseases Inactive 28-Oct-2010 00000000000
EP-2633054-A1 New compositions and methods for treatment of autoimmune and allergic diseases Active 28-Oct-2010 00000000000
EP-2633054-B1 New compositions and methods for treatment of autoimmune and allergic diseases Inactive 28-Oct-2010 A61K39/0008
To view Toleranzia’s complete patent history, request access »

Toleranzia Executive Team (5)

Name Title Board Seat Contact Info
Charlotte Fribert Ph.D Chief Executive Officer
Torbjörn Sannerstedt Chief Financial Officer
Björn Löwenadler Chief Business Officer
Vidar Wendel-Hansen Chief Medical Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Toleranzia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Toleranzia Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Toleranzia‘s full profile, request access.

Request a free trial